These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 14647530)

  • 1. Neuropharmacological profile of an atypical antipsychotic, NRA0562.
    Hirota S; Kawashima N; Chaki S; Okuyama S
    CNS Drug Rev; 2003; 9(4):375-88. PubMed ID: 14647530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.
    Funakoshi T; Chaki S; Kawashima N; Suzuki Y; Yoshikawa R; Kumagai T; Nakazato A; Kameo K; Goto M; Okuyama S
    Life Sci; 2002 Aug; 71(12):1371-84. PubMed ID: 12127158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats.
    Kawashima N; Funakoshi T; Omura T; Chaki S; Kameo K; Okuyama S
    Eur J Pharmacol; 2001 Jun; 423(1):27-33. PubMed ID: 11438303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
    Chaki S; Funakoshi T; Yoshikawa R; Okuyama S; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    Neuropharmacology; 1999 Aug; 38(8):1185-94. PubMed ID: 10462131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562) in rats.
    Takamori K; Funakoshi T; Hirota S; Chaki S; Kameo K
    Life Sci; 2002 Jul; 71(8):947-52. PubMed ID: 12084391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.
    Okuyama S; Kawashima N; Chaki S; Yoshikawa R; Funakoshi T; Ogawa SI; Suzuki Y; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    Life Sci; 1999; 65(20):2109-25. PubMed ID: 10579464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
    Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
    Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
    Howard HR; Lowe JA; Seeger TF; Seymour PA; Zorn SH; Maloney PR; Ewing FE; Newman ME; Schmidt AW; Furman JS; Robinson GL; Jackson E; Johnson C; Morrone J
    J Med Chem; 1996 Jan; 39(1):143-8. PubMed ID: 8568801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
    Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
    Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
    J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
    Sorensen SM; Kehne JH; Fadayel GM; Humphreys TM; Ketteler HJ; Sullivan CK; Taylor VL; Schmidt CJ
    J Pharmacol Exp Ther; 1993 Aug; 266(2):684-91. PubMed ID: 8102646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone.
    Cohen LJ
    Pharmacotherapy; 1994; 14(3):253-65. PubMed ID: 7524043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics.
    Meltzer HY
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):2S-3S. PubMed ID: 7730497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.